{"id":"https://openalex.org/W7116841949","doi":"https://doi.org/10.1136/jitc-2025-013222","title":"Botensilimab (Fc-enhanced anti\u2013CTLA-4 antibody) plus balstilimab (anti\u2013PD-1 antibody) in patients with treatment-refractory ovarian cancer","display_name":"Botensilimab (Fc-enhanced anti\u2013CTLA-4 antibody) plus balstilimab (anti\u2013PD-1 antibody) in patients with treatment-refractory ovarian cancer","publication_year":2025,"publication_date":"2025-12-01","ids":{"openalex":"https://openalex.org/W7116841949","doi":"https://doi.org/10.1136/jitc-2025-013222","pmid":"https://pubmed.ncbi.nlm.nih.gov/41436232","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/12730848"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2025-013222","doi":"https://doi.org/10.1136/jitc-2025-013222","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-013222","pdf_url":"https://jitc.bmj.com/content/13/12/e013222.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7116841949"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/13/12/e013222.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081806932","display_name":"Rebecca L. Porter","orcid":"https://orcid.org/0000-0002-4848-1275","observed_orcids":["https://orcid.org/0000-0002-4848-1275"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rebecca Porter","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0002-4848-1275","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068892140","display_name":"Bruno Bockorny","orcid":"https://orcid.org/0000-0002-9162-1560","observed_orcids":["https://orcid.org/0000-0002-9162-1560"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruno Bockorny","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040451836","display_name":"Bradley R. Corr","orcid":"https://orcid.org/0000-0002-6608-2585","observed_orcids":["https://orcid.org/0000-0002-6608-2585"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bradley R Corr","raw_affiliation_strings":["University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I51713134"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daruka Mahadevan","raw_affiliation_strings":["The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA"],"raw_orcid":"https://orcid.org/0000-0002-7129-5593","affiliations":[{"raw_affiliation_string":"The University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004799762","display_name":"Breelyn Ann Wilky","orcid":"https://orcid.org/0000-0001-5080-497X","observed_orcids":["https://orcid.org/0000-0001-5080-497X"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]},{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Breelyn A Wilky","raw_affiliation_strings":["University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA","institution_ids":["https://openalex.org/I4210134151","https://openalex.org/I51713134"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013744957","display_name":"Anthony B. El-Khoueiry","orcid":"https://orcid.org/0000-0002-9053-3841","observed_orcids":["https://orcid.org/0000-0002-9053-3841"]},"institutions":[{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony B El-Khoueiry","raw_affiliation_strings":["University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071193838","display_name":"Andrea J. Bullock","orcid":"https://orcid.org/0000-0001-7143-0225","observed_orcids":["https://orcid.org/0000-0001-7143-0225"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea J Bullock","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0001-7143-0225","affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005836117","display_name":"Navid Hafez","orcid":"https://orcid.org/0000-0001-8115-9328","observed_orcids":["https://orcid.org/0000-0001-8115-9328"]},"institutions":[{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Navid Hafez","raw_affiliation_strings":["The Angeles Clinic and Research Institute, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinic and Research Institute, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027673468","display_name":"Justin Moser","orcid":"https://orcid.org/0000-0002-0643-6759","observed_orcids":["https://orcid.org/0000-0002-0643-6759"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin Moser","raw_affiliation_strings":["HonorHealth Research Institute, Scottsdale, Arizona, USA"],"raw_orcid":"https://orcid.org/0000-0002-0643-6759","affiliations":[{"raw_affiliation_string":"HonorHealth Research Institute, Scottsdale, Arizona, USA","institution_ids":["https://openalex.org/I4210130412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108293870","display_name":"Anastasia Martynova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anastasia Martynova","raw_affiliation_strings":["University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079409805","display_name":"Justin Stebbing","orcid":"https://orcid.org/0000-0002-1117-6947","observed_orcids":["https://orcid.org/0000-0002-1117-6947"]},"institutions":[{"id":"https://openalex.org/I51216347","display_name":"Anglia Ruskin University","ror":"https://ror.org/0009t4v78","country_code":"GB","type":"education","lineage":["https://openalex.org/I51216347"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Justin Stebbing","raw_affiliation_strings":["Anglia Ruskin University, School of Life Sciences, Cambridge, England, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Anglia Ruskin University, School of Life Sciences, Cambridge, England, UK","institution_ids":["https://openalex.org/I51216347"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102729927","display_name":"Bishnu P. Joshi","orcid":"https://orcid.org/0000-0001-8829-5306","observed_orcids":["https://orcid.org/0000-0001-8829-5306"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bishnu Joshi","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106109825","display_name":"Sean Bourdelais","orcid":"https://orcid.org/0009-0008-5811-1930","observed_orcids":["https://orcid.org/0009-0008-5811-1930"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Bourdelais","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chloe Delepine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chloe Delepine","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080150466","display_name":"Dhan Sidhartha Chand","orcid":"https://orcid.org/0009-0003-8124-4399","observed_orcids":["https://orcid.org/0009-0003-8124-4399"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dhan Chand","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0009-0003-8124-4399","affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121034501","display_name":"Wei Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Wu","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010363210","display_name":"Benny Johnson","orcid":"https://orcid.org/0000-0003-3683-8115","observed_orcids":["https://orcid.org/0000-0003-3683-8115","https://orcid.org/0000-0002-6826-6687"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benny Johnson","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073582280","display_name":"Joseph Elan Grossman","orcid":"https://orcid.org/0000-0002-2130-2783","observed_orcids":["https://orcid.org/0000-0002-2130-2783"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph E Grossman","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060495866","display_name":"Steven J O'Day","orcid":"https://orcid.org/0009-0005-5345-5417","observed_orcids":["https://orcid.org/0009-0005-5345-5417"]},"institutions":[{"id":"https://openalex.org/I2963242126","display_name":"Agenus (United States)","ror":"https://ror.org/03dwhj404","country_code":"US","type":"company","lineage":["https://openalex.org/I2963242126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J O\u2019Day","raw_affiliation_strings":["Agenus Inc, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Agenus Inc, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I2963242126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058249824","display_name":"Ursula A. Matulonis","orcid":"https://orcid.org/0000-0002-3103-6992","observed_orcids":["https://orcid.org/0000-0002-3103-6992"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ursula A Matulonis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069690249","display_name":"Michael S. Gordon","orcid":"https://orcid.org/0000-0002-7679-9504","observed_orcids":["https://orcid.org/0000-0002-7679-9504"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S Gordon","raw_affiliation_strings":["HonorHealth Research Institute, Scottsdale, Arizona, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HonorHealth Research Institute, Scottsdale, Arizona, USA","institution_ids":["https://openalex.org/I4210130412"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5081806932"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":1.8426,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.84947432,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"13","issue":"12","first_page":"e013222","last_page":"e013222"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.49709999561309814,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.49709999561309814,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.490200012922287,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/botensilimab","display_name":"botensilimab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/balstilimab","display_name":"balstilimab","score":0.9620000123977661},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9750000238418579},{"id":"https://openalex.org/keywords/platinum-resistant-ovarian-cancer","display_name":"platinum-resistant ovarian cancer","score":0.9639999866485596},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7620000243186951},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8209999799728394},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7279999852180481},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.7179999947547913},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9319999814033508},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7110000252723694},{"id":"https://openalex.org/keywords/immunophenotyping","display_name":"immunophenotyping","score":0.4909999966621399},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6029999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9007999897003174},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6277999877929688},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.598800003528595},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5925999879837036},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5496000051498413},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4350999891757965},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3921999931335449},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3352999985218048},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.27559998631477356},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.2653000056743622}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1136/jitc-2025-013222","doi":"https://doi.org/10.1136/jitc-2025-013222","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-013222","pdf_url":"https://jitc.bmj.com/content/13/12/e013222.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},{"id":"pmid:41436232","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41436232","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12730848","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12730848/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Immunother Cancer","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:263889b29380477c93b5a2551db21583","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/263889b29380477c93b5a2551db21583","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 13, Iss 12 (2025)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2025-013222","doi":"https://doi.org/10.1136/jitc-2025-013222","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2025-013222","pdf_url":"https://jitc.bmj.com/content/13/12/e013222.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7116841949.pdf","grobid_xml":"https://content.openalex.org/works/W7116841949.grobid-xml"},"referenced_works_count":40,"referenced_works":["https://openalex.org/W2097995306","https://openalex.org/W2105459360","https://openalex.org/W2137074525","https://openalex.org/W2150640296","https://openalex.org/W2410778127","https://openalex.org/W2549481046","https://openalex.org/W2584617802","https://openalex.org/W2742763599","https://openalex.org/W2808202038","https://openalex.org/W2890261294","https://openalex.org/W2897516580","https://openalex.org/W2907564726","https://openalex.org/W2911940503","https://openalex.org/W2931644395","https://openalex.org/W2945674342","https://openalex.org/W2952108487","https://openalex.org/W3016085372","https://openalex.org/W3025130660","https://openalex.org/W3128646645","https://openalex.org/W3138881971","https://openalex.org/W3193486106","https://openalex.org/W3194911083","https://openalex.org/W3198783816","https://openalex.org/W3210474759","https://openalex.org/W4200215773","https://openalex.org/W4280592201","https://openalex.org/W4308383986","https://openalex.org/W4317871276","https://openalex.org/W4318580181","https://openalex.org/W4364378625","https://openalex.org/W4377220075","https://openalex.org/W4380149145","https://openalex.org/W4385975843","https://openalex.org/W4389376362","https://openalex.org/W4390946922","https://openalex.org/W4399452795","https://openalex.org/W4399640828","https://openalex.org/W4401163578","https://openalex.org/W4402559970","https://openalex.org/W4406854611"],"related_works":["https://openalex.org/W7127104568","https://openalex.org/W4386948493","https://openalex.org/W7219765685","https://openalex.org/W4308383986","https://openalex.org/W4402704870","https://openalex.org/W4412397002","https://openalex.org/W4387826496","https://openalex.org/W7162564646","https://openalex.org/W7162507116","https://openalex.org/W4399407152"],"abstract_inverted_index":{"BACKGROUND:":[0],"Patients":[1],"with":[2,39,63,83,177,310,325],"platinum-resistant/refractory":[3],"ovarian":[4,65,312],"cancer":[5,313],"(PROC)":[6],"experience":[7],"suboptimal":[8],"outcomes,":[9],"highlighting":[10],"an":[11,58,134],"immediate":[12],"need":[13],"for":[14,144,163,335],"novel":[15],"therapies.":[16],"This":[17],"phase":[18],"1b":[19],"study":[20],"investigated":[21],"the":[22],"safety":[23,102,145],"and":[24,103,117,161,198,249,262,270,286,289,305,341],"efficacy":[25],"of":[26,42,61,114,149,153,347,361],"botensilimab":[27],"(BOT),":[28],"a":[29,147,279],"fragment":[30],"crystallizable":[31],"(Fc)-enhanced":[32],"anti-cytotoxic":[33],"T-lymphocyte-associated":[34],"antigen":[35],"4":[36],"(CTLA-4)":[37],"antibody":[38],"differentiated":[40],"mechanisms":[41],"action":[43],"from":[44],"first-generation":[45],"CTLA-4":[46],"inhibitors,":[47],"plus":[48],"balstilimab":[49],"(BAL;":[50],"anti-programmed":[51],"cell":[52],"death":[53],"protein":[54],"1":[55,73,274],"antibody),":[56],"in":[57,81,125,276,291,308,349],"expanded":[59],"cohort":[60],"patients":[62,141,309,327],"treatment-refractory":[64,311],"cancer.":[66],"METHODS:":[67],"BOT":[68],"was":[69,133,171,183,209,219,231,241,252],"administered":[70],"intravenously":[71,85],"at":[72,86],"mg/kg":[74,77,88],"or":[75,204],"2":[76,90,94],"every":[78,89],"6":[79],"weeks":[80,91],"combination":[82,300],"BAL":[84],"3":[87,150],"(up":[92],"to":[93,100,189,215,225,237,247,257],"years).":[95],"The":[96,165,298,343],"primary":[97],"objectives":[98],"were":[99,142,339],"assess":[101],"tolerability.":[104],"Efficacy":[105],"end":[106,136],"points":[107],"included":[108],"objective":[109],"response":[110,115],"rate":[111,201],"(ORR),":[112],"duration":[113],"(DOR),":[116],"progression-free":[118],"survival":[119,131],"(PFS)":[120],"by":[121],"Response":[122],"Evaluation":[123],"Criteria":[124],"Solid":[126],"Tumors":[127],"(RECIST)":[128],"V.1.1.":[129],"Overall":[130],"(OS)":[132],"exploratory":[135],"point.":[137],"RESULTS:":[138],"Overall,":[139],"44":[140],"evaluable":[143],"(with":[146],"median":[148,155,229,239],"prior":[151],"lines":[152],"therapy;":[154],"follow-up":[156],"9.6":[157],"months":[158,221,233,243],"(range,":[159],"0.6-36.6)),":[160],"35":[162],"efficacy.":[164],"most":[166],"common":[167],"treatment-related":[168,179],"adverse":[169],"event":[170],"diarrhea/colitis":[172],"(43%;":[173],"16%":[174],"grade":[175],"3)":[176],"no":[178,315],"deaths.":[180],"RECIST-confirmed":[181],"ORR":[182],"23%":[184],"(8/35;":[185],"95%":[186,212],"CI":[187,213,223,235,245,255],"10%":[188],"40%;":[190],"one":[191],"complete":[192,306],"(CR),":[193],"seven":[194],"partial":[195],"responses":[196,304],"(PRs))":[197],"clinical":[199,287,323,345],"benefit":[200,324],"(CR,":[202],"PR,":[203],"stable":[205,331],"disease":[206,332],"\u226524":[207,336],"weeks)":[208],"31%":[210],"(11/35;":[211],"17%":[214],"49%).":[216],"Median":[217],"DOR":[218],"9.7":[220],"(95%":[222,234,244,254],"2.8":[224,232],"not":[226],"reached":[227],"(NR)),":[228],"PFS":[230],"1.4":[236],"5.5),":[238],"OS":[240,251],"14.8":[242],"12.1":[246],"NR),":[248],"12-month":[250],"75%":[253],"55%":[256],"86%).":[258],"Immune":[259],"phenotypic":[260],"analyses":[261],"biomarker":[263,356],"data":[264],"revealed":[265],"significantly":[266],"higher":[267,271],"Fc\u03b3RIIIA+CD11c+":[268],"cells":[269],"programmed":[272],"death-ligand":[273],"expression":[275],"responding":[277],"patients,":[278,352],"strong":[280],"association":[281],"between":[282],"T-cell":[283],"infiltrated":[284],"tumors":[285],"benefit,":[288],"differences":[290],"immune":[292],"architecture":[293],"across":[294],"histologic":[295],"subtypes.":[296],"CONCLUSION:":[297],"BOT/BAL":[299,348],"demonstrated":[301],"deep,":[302],"durable":[303],"remissions":[307],"where":[314],"standard":[316],"treatments":[317],"are":[318],"currently":[319],"available.":[320],"RECIST":[321],"under-represented":[322],"11":[326],"achieving":[328],"prolonged/clinically":[329],"meaningful":[330],"(or":[333],"better)":[334],"weeks.":[337],"Toxicities":[338],"manageable":[340],"reversible.":[342],"encouraging":[344],"activity":[346],"heavily":[350],"pretreated":[351],"as":[353,355],"well":[354],"associations,":[357],"warrants":[358],"further":[359],"investigation":[360],"this":[362],"combination.":[363]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2025-12-23T00:00:00"}